Biotechnology
Gene therapy: correcting the code in patients
Builds on: Reading the genome (gene expression, RNA interference), From rDNA to gene editing (CRISPR) and Stem cells (blood stem cells, thalassaemia and sickle cell disease).
In a nutshell
Gene therapy treats disease by delivering genetic material into a patient's cells: to edit a faulty gene, to add a working copy, or to regulate how a gene is read. It works best where one known gene causes the disease, which is why blood disorders such as sickle cell disease, thalassaemia and haemophilia, and blood cancers treated with engineered immune cells, came first. The challenges are getting the gene into the right cells safely, and the cost.
- What is changed: the DNA (permanent) or the RNA (temporary).
- Where: inside the body (in vivo) or in cells taken out and returned (ex vivo).
- How it is carried: viral vectors (lentivirus, AAV) or non-viral carriers (lipid nanoparticles).
Faulty geneEdit, add or regulateWorking protein
"India launches its first indigenous CRISPR gene therapy for sickle cell disease"
In November 2025 the government launched BIRSA 101, named after the tribal leader Birsa Munda, and transferred the technology to the Serum Institute of India. Sickle cell disease is concentrated among tribal communities of central and eastern India, and the only established cure, a bone marrow transplant, needs a matched donor. A gene therapy approved abroad costs crores of rupees. How can editing a patient's own cells cure an inherited blood disease, and why do such therapies cost so much?
Earlier (see Stem cells) we met cell therapy, in which cells are the medicine: a bone marrow transplant, or cells grown from stem cells. Gene therapy is different: the medicine is a gene, or a tool that changes genes, delivered into the patient's own cells. The two often meet, as when blood stem cells are taken out, edited and returned.
Three ways to act on genes
| Approach | What it does | How long it lasts | Example |
|---|---|---|---|
| Gene editing | Switches a gene off (knock-out), corrects letters, or disables a switch, using CRISPR or base editing | Permanent in the edited cells and their descendants | Casgevy for sickle cell disease and thalassaemia |
| Gene addition (augmentation) | Delivers a working copy of a gene, or an entirely new gene, without removing the faulty one | Long-lasting; permanent if the gene is inserted into dividing cells' DNA | Haemophilia A gene therapy at CMC Vellore; CAR-T cells |
| Gene regulation (RNA-based) | Supplies an mRNA so cells make a protein for a while; or silences a harmful mRNA with siRNA or antisense strands (see Reading the genome) | Temporary; repeated doses needed | Patisiran (siRNA); mRNA vaccines (see Therapeutics and vaccines) |
MicroRNAs are not usually delivered as medicines, because each one regulates many genes and its effects would be hard to control. They are used instead as biomarkers, for example for early detection of cancer, and as targets for drugs.
Why blood disorders came first
Most diseases involve many genes and the environment, so there is no single gene to fix. Gene therapy works where one gene with a known defect causes the disease: a monogenic disease. Many monogenic diseases are rare; India's National Policy for Rare Diseases, 2021, supports treatment for some of them. Blood disorders are especially suitable for a second reason: blood is made continuously by stem cells in the bone marrow, which can be collected from the blood, edited in a laboratory and returned. Once the edited stem cells settle back in the marrow, they keep producing corrected cells for life. The same is true of immune cells, which are also blood cells.
- Sickle cell disease and beta-thalassaemia are caused by defects in the HBB gene for the beta chain of adult haemoglobin (see Stem cells).
- Haemophilia is caused by a missing clotting factor (factor VIII in haemophilia A, factor IX in haemophilia B), so wounds keep bleeding. The genes are on the X chromosome, so it affects mainly boys. India has the world's second-largest number of people with haemophilia.
- Severe combined immunodeficiency (SCID), the "bubble boy" disease, leaves a child with almost no working immune system. The first approved gene therapy trial, in the United States in 1990, treated a girl with one form of SCID.
Sickle cell disease: Casgevy and BIRSA 101
Before birth, a foetus makes a different kind of haemoglobin, foetal haemoglobin, from genes that are switched off after birth when adult haemoglobin takes over. Foetal haemoglobin does not sickle, and people who naturally keep making some of it as adults have milder sickle cell disease. Casgevy uses this. Blood stem cells are collected from the patient; CRISPR-Cas9 disables a genetic switch (in a gene called BCL11A) that keeps foetal haemoglobin turned off; the patient's marrow is cleared with chemotherapy; and the edited cells are returned. Their red cells now carry foetal haemoglobin, and in trials most patients were freed of painful crises or, in thalassaemia, of the need for transfusions.
Casgevy was approved in the United Kingdom in November 2023 and in the United States in December 2023, the first approved medicine based on CRISPR. (It was not the first gene therapy: gene therapies using viral vectors had been approved in several countries for years.) Its price abroad runs into crores of rupees per patient, and the treatment needs specialised hospitals and harsh chemotherapy.
BIRSA 101, developed at CSIR's Institute of Genomics and Integrative Biology, Delhi, uses an Indian-engineered, highly precise version of Cas9 called enFnCas9 to edit the patient's own blood stem cells outside the body. The aim is a far cheaper therapy for the disease burden among India's tribal communities, in line with the National Sickle Cell Anaemia Elimination Mission (launched 2023, target 2047). At its launch, first-phase clinical trials with AIIMS Delhi were planned to begin in 2026.
Haemophilia A: gene addition at CMC Vellore
People with severe haemophilia A need frequent, expensive infusions of factor VIII. Scientists at the Centre for Stem Cell Research, Christian Medical College, Vellore, supported by the Department of Biotechnology, took blood stem cells from five patients, used a lentiviral vector to add a working factor VIII gene, and returned the cells. Results published in December 2024 showed no bleeding episodes in any of the five during follow-up. This was India's first human gene therapy trial for haemophilia and a first-in-human use of this lentiviral approach for haemophilia A. Note that this is gene addition: a working gene is supplied, not the faulty one edited.
CAR-T cells: training the immune system against cancer
Cancer cells are the body's own cells, so the immune system often fails to recognise them as targets (see Therapeutics and vaccines). T cells are immune cells that kill infected or abnormal cells when they recognise a marker (an antigen) on them. In CAR-T cell therapy, a patient's T cells are collected and given a new gene for a man-made receptor, a chimeric antigen receptor (CAR), that recognises a marker on the cancer cells. ("Chimeric" because it joins parts from different proteins.) The engineered cells are multiplied and infused back, where they hunt down cells carrying the marker. Most approved CAR-T therapies target CD19, a marker on certain blood cancers of B cells, such as some leukaemias and lymphomas.
India's first CAR-T therapy, NexCAR19, was developed by ImmunoACT, a company incubated at IIT Bombay, with Tata Memorial Centre. It was approved by the Central Drugs Standard Control Organisation in October 2023 and launched in 2024, at a fraction of the cost of CAR-T therapies abroad. CAR-T works so far mainly against blood cancers, not solid tumours, and can cause severe immune side effects.
Two related discoveries show where immune therapies are heading. The 2025 Nobel Prize in Physiology or Medicine was awarded for the discovery of regulatory T cells, which act as the immune system's brakes and stop it attacking the body's own tissues. Understanding them could help treat autoimmune diseases such as type 1 diabetes and help transplanted organs, including the gene-edited pig organs described earlier, avoid rejection.
Delivering the gene
In vivo and ex vivo
- Ex vivo ("outside the living body"): cells are taken out, modified in a laboratory and returned. Casgevy, BIRSA 101, the Vellore haemophilia therapy and CAR-T cells are all ex vivo. It allows the edited cells to be checked before use, but it is complex and costly.
- In vivo ("inside the living body"): the gene or editing tool is delivered directly into the body, for example injected into the eye or the bloodstream. In 2025 doctors in the United States treated an infant with a rare liver disease using a base editor designed for his own mutation and delivered in vivo, a first for personalised editing.
Viral and non-viral vectors
Viruses are natural experts at getting genes into cells, so disabled viruses, with their disease-causing genes removed, are the commonest carriers.
| Vector | Nature | Inserts into the cell's DNA? | Suited to |
|---|---|---|---|
| Retrovirus and lentivirus (a kind of retrovirus, derived from HIV) | RNA viruses that use reverse transcriptase | Yes: the gene is copied into every daughter cell | Dividing cells such as blood stem cells and T cells; CAR-T, Vellore haemophilia therapy |
| Adeno-associated virus (AAV) | Small DNA virus that causes no known disease | Mostly not: the gene stays separate in the nucleus | Non-dividing cells, such as in the retina, muscle and liver; e.g. an approved therapy for an inherited form of blindness |
| Adenovirus | DNA virus (some cause colds) | No | Short-term expression; vaccines |
| Non-viral: lipid nanoparticles, naked DNA or mRNA | Fatty bubbles or bare genetic material | No | mRNA vaccines; in vivo editing of the liver |
Each has risks. A vector that inserts itself can land in the wrong place and switch on a cancer-causing gene (insertional mutagenesis), which happened in some early trials. The immune system may attack the viral vector. Non-viral carriers avoid infection risks but are less efficient at getting into most tissues.
Somatic and germline: where the line is drawn
All the therapies above change somatic cells (body cells), so the change stays with the patient and is not inherited. Changing the germline, eggs, sperm or embryos, would alter every cell of the resulting person and pass the change to future generations. In 2018 the Chinese scientist He Jiankui announced the birth of twin girls whose embryos he had edited to disable the CCR5 gene (the HIV entry receptor of The cell); the work was condemned worldwide and he was jailed. In India, the ICMR's National Guidelines for Gene Therapy Product Development and Clinical Trials (2019) permit somatic gene therapy under regulation and prohibit germline gene therapy; gene therapy products need approval from the Central Drugs Standard Control Organisation. (Mitochondrial replacement is a related heritable change: see DNA and heredity.)
The larger policy questions are about access. Gene therapies are among the most expensive medicines in the world, need advanced hospitals, and are developed mostly for patients in rich countries, while diseases such as sickle cell are commonest in Africa and India. Home-grown therapies such as NexCAR19, the Vellore haemophilia therapy and BIRSA 101 matter because they aim to bring the cost down by an order of magnitude.
Gene therapies at a glance
| Therapy | Disease | Approach | Ex vivo or in vivo | Status |
|---|---|---|---|---|
| Casgevy | Sickle cell disease, beta-thalassaemia | CRISPR edit switching on foetal haemoglobin | Ex vivo | Approved UK and US, 2023: first CRISPR medicine |
| BIRSA 101 (CSIR-IGIB) | Sickle cell disease | CRISPR editing with enFnCas9 | Ex vivo | Launched Nov 2025; trials planned |
| CMC Vellore therapy | Haemophilia A | Gene addition (factor VIII) by lentivirus | Ex vivo | Early trial, results 2024 |
| NexCAR19 (ImmunoACT, IIT Bombay, Tata Memorial) | B-cell blood cancers | Gene addition: CAR targeting CD19 | Ex vivo | Approved in India, 2023 |
| Patisiran | A rare inherited nerve disease | siRNA silencing | In vivo | Approved US, 2018 |
Recent developments
Nobel Prize in Physiology or Medicine 2026: light-gated ion channels and optogenetics
The 2026 prize went to Karl Deisseroth (United States) and Peter Hegemann and Georg Nagel (Germany) for their discoveries concerning light-gated ion channels and optogenetics. Hegemann and Nagel established that algae carry channelrhodopsins, membrane proteins that open an ion channel when light falls on them. Deisseroth put the gene for such a protein into nerve cells, so that a pulse of light can switch a chosen neuron on or off.
Why it matters: The method rests on two facts from this chapter rather than on neuroscience alone: a gene taken from an alga can be read by a mammalian cell because the genetic code is shared, and a virus can be used to carry that gene into one chosen type of cell. It is also a clear case of a single protein in the membrane doing a specific job, which is what makes a cell more than a bag of chemicals.
Remember: Channelrhodopsin comes from algae; the gene is delivered into neurons by a viral vector; light then controls when that cell fires. Recent medicine prizes: 2026 optogenetics (Deisseroth, Hegemann, Nagel); 2025 peripheral immune tolerance (Brunkow, Ramsdell, Sakaguchi); 2024 microRNA (Ambros, Ruvkun).
BIRSA 101: an Indian gene-editing platform aimed at sickle cell disease
CSIR-IGIB launched BIRSA 101, described as India's first indigenous CRISPR-based gene therapy for sickle cell disease. It uses enFnCas9, an editing protein engineered at the institute rather than licensed from abroad: stem cells are taken from the patient, the gene is edited, and the cells are returned so that normal haemoglobin is produced. It was launched on 19 November 2025, named for the 150th birth anniversary of Birsa Munda, and a technology-transfer agreement was signed with Serum Institute of India for scale-up and trials.
Why it matters: Sickle cell disease is concentrated in tribal and central Indian districts, where the gene therapies approved abroad, priced at Rs 20 to 25 crore, are irrelevant in practice. An Indian editing protein matters for two separate reasons: it avoids the patent stack around Cas9, and it allows the cost of the whole procedure to be designed for Indian conditions. The platform is at the start of that road: a launch and a technology-transfer agreement are not an approved treatment, and the edited-stem-cell route still requires the demanding hospital procedure that goes with a bone-marrow transplant.
Remember: BIRSA 101 - CSIR-IGIB, launched 19 November 2025, named after Birsa Munda, aimed at sickle cell disease, built on the indigenous enFnCas9 protein, technology transferred to Serum Institute of India. Distinguish it from Casgevy, the CRISPR therapy approved abroad in 2023 for sickle cell disease and beta-thalassaemia. It supports the goal of a sickle-cell-free India by 2047.
Source: BioSpectrum India, November 2025
Last-month notes
- Gene therapy: editing (permanent), addition, RNA-based regulation (temporary). Works best for monogenic diseases; blood disorders first.
- First gene therapy trial: 1990 (US), for a form of SCID. National Policy for Rare Diseases, 2021.
- Casgevy: CRISPR disables BCL11A switch → foetal haemoglobin; ex vivo; approved UK Nov 2023, US Dec 2023; first CRISPR medicine.
- BIRSA 101: CSIR-IGIB, enFnCas9, launched Nov 2025, technology to Serum Institute. National Sickle Cell Anaemia Elimination Mission (2023, target 2047).
- CMC Vellore: haemophilia A, lentiviral factor VIII gene addition, five patients, zero bleeds (results Dec 2024).
- CAR-T: chimeric antigen receptor on patient's T cells; NexCAR19 (ImmunoACT/IIT Bombay, Tata Memorial), approved Oct 2023. Nobel Medicine 2025: regulatory T cells.
- Vectors: lentivirus/retrovirus integrate (dividing cells); AAV mostly does not (non-dividing cells: retina, muscle, liver); lipid nanoparticles (mRNA).
- Somatic vs germline; He Jiankui (2018, CCR5). ICMR gene therapy guidelines 2019: germline prohibited.
Statements to watch for
- Casgevy is the first approved CRISPR therapy, not the first gene therapy.
- Gene therapy can add a whole working gene with a viral vector; it is not limited to editing.
- CAR-T cell therapy is done ex vivo.
- Somatic gene therapy is not inherited; germline changes would be.
- Haemophilia genes are on the X chromosome, which is why it mostly affects males.
- siRNA is given as a medicine; microRNA is mainly a biomarker and a drug target.
Revise and apply
Activities to check your understanding, not new content. Answer first, then press Check or Show answers. Multiple-choice questions are original, in the UPSC style, not past UPSC questions. A printable workbook with all activities is on the theme page.
Type the missing words, then check.
(a) editing (b) addition (c) regulation (d) foetal (e) birsa (f) car (g) nexcar19 (h) lentivirus (i) aav
- A disease caused by a defect in a single known gene is called a disease.
- Casgevy works by disabling a switch so that cells resume making haemoglobin.
- Gene therapy carried out on cells taken from the patient and returned is called .
- The 2025 Nobel Prize in Physiology or Medicine recognised the discovery of T cells.
- Changes made to eggs, sperm or embryos affect the , and are prohibited in India.
1. monogenic · 2. foetal · 3. ex vivo · 4. regulatory · 5. germline
- Casgevy
- NexCAR19
- CMC Vellore lentiviral therapy
- BIRSA 101
Casgevy: Sickle cell disease and beta-thalassaemia · NexCAR19: B-cell blood cancers · CMC Vellore lentiviral therapy: Haemophilia A · BIRSA 101: Sickle cell disease, developed in India
- Casgevy was the first gene therapy of any kind to be approved anywhere. It was the first approved therapy based on CRISPR; earlier gene therapies used viral vectors.
- CAR-T cell therapy modifies the patient's own immune cells outside the body.
- Somatic gene therapy changes are passed on to the patient's children. Only germline changes would be inherited.
- Adeno-associated virus vectors usually insert the new gene into the cell's chromosomes. The gene mostly stays separate in the nucleus, which suits non-dividing cells.
- Gene therapy has been most successful so far in blood and immune disorders.
1. False: It was the first approved therapy based on CRISPR; earlier gene therapies used viral vectors. 2. True. 3. False: Only germline changes would be inherited. 4. False: The gene mostly stays separate in the nucleus, which suits non-dividing cells. 5. True.
"India launches its own CRISPR gene therapy for sickle cell disease." (a) Why are blood disorders the first target of gene therapy? (b) Why does an indigenous therapy matter here?
(a) Sickle cell disease is caused by a defect in one known gene, and blood stem cells can be collected, edited outside the body and returned, after which they keep making corrected cells. (b) The approved foreign therapy costs crores per patient; the disease burden in India falls largely on tribal communities, so an affordable home-grown therapy is what makes elimination targets realistic.
Consider the following statements about gene therapy:
- It has been most successful in diseases caused by a defect in a single gene.
- In ex vivo gene therapy, the patient's cells are modified outside the body and returned.
- Somatic gene therapy alters the genes passed on to the patient's children.
Which of the statements given above are correct?
Answer: (a). Somatic gene therapy changes body cells only; inherited change would require editing the germline, which is prohibited in India.
What it tests: monogenic diseases, ex vivo therapy and the somatic-germline distinction.
CAR-T cell therapy involves:
Answer: (b). A gene for a chimeric antigen receptor is added to the patient's T cells outside the body; the cells are multiplied and infused back to attack cells carrying that marker. Most approved CAR-T therapies target CD19 on B-cell cancers.
What it tests: what CAR-T therapy does, and that it modifies immune cells, not the tumour.
What is gene therapy, and what limits its wider use? Answer in about 50 words.
Points to include: Delivering genes or gene-editing tools into a patient's cells to correct, add or regulate a gene; suited to monogenic diseases, especially of blood and immune cells. Limits: most diseases are not monogenic; delivery into the right tissue; risks of insertional mutagenesis and immune reactions to vectors; harsh conditioning; very high cost and need for advanced hospitals.
The next question Beyond changing genes, biotechnology makes many of the medicines and vaccines we use every day. How are therapeutic proteins and antibodies made, how do different vaccines train the immune system, and how is biotechnology changing the fight against cancer and drug-resistant microbes?